BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy

BioNTech and Bristol Myers Squibb announced positive Phase 2 data for pumitamig (BNT327/BMS986545), a PD-L1xVEGF-A bispecific immunomodulator, combined with docetaxel in patients with advanced NSCLC who progressed after first-line immunotherapy plus chemotherapy. The trial showed a confirmed objective response rate of 36.7%, median progression-free survival of 6.9 months, and a manageable safety profile, demonstrating potential improvement over standard-of-care docetaxel which typically delivers 3.6-3.9 months PFS.